The combination of a strong Q3 beat, raised full-year guidance, a new $250M buyback authorization, and a credit rating upgrade signals accelerating operational momentum and management confidence. Monitor the Q4 earnings call for updates on the de novo pipeline and M&A execution, as well as any commentary on the new CEO's strategic priorities.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 6 $42.22entry
- T+1 · 3d ago +0.43%α −1.94% · $42.40
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 25d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Concentra reported Q3 2026 revenue of $622.1M (+8.6% YoY) and GAAP EPS of $0.52 (+36.8% YoY), beating consensus estimates of $0.44 EPS and $605.4M revenue. The company raised its full-year 2026 revenue guidance to $2.36B-$2.38B and Adjusted EBITDA guidance to $505M-$510M, announced a new $250M share repurchase program, and completed a leadership transition with Matt DiCanio as CEO.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $622.1M, +8.6% YoY from $572.8M
- GAAP EPS $0.52, +36.8% YoY from $0.38
- Adjusted EBITDA $140.2M, +17.9% YoY, margin expanded 178bps to 22.5%
- Net income $67.8M, +36.0% YoY; net income margin expanded 220bps to 10.9%
- Patient visits +4.9% YoY to 58,312 per day; revenue per visit +3.3% to $152.14
- Raised FY 2026 revenue guidance to $2.36B-$2.38B (from $2.325B-$2.375B)
- Raised FY 2026 Adjusted EBITDA guidance to $505M-$510M (from $485M-$495M)
- Board authorized new $250M share repurchase program with no expiration
- Net leverage ratio improved to 2.90x; S&P upgraded credit rating from BB- to BB
- CEO transition completed: Matt DiCanio succeeded Keith Newton as CEO effective Nov 1
Financial Impact
Q3 revenue beat consensus by $16.7M (2.8%); GAAP EPS beat consensus by $0.08 (18.2%); FY guidance raised for both revenue and EBITDA
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Occupational health centers - Workers compensation | $370.5M | +7.9% |
| Occupational health centers - Employer services | $190.5M | +10.0% |
| Occupational health centers - Consumer health | $6.7M | -9.0% |
| Occupational health centers - Other | $1.9M | -3.6% |
| Onsite health clinics | $38.4M | +10.0% |
| Other | $14.1M | +18.4% |
Risk Factors
- Consumer health visits declined 6.7% YoY, a small but persistent negative trend
- Free cash flow in Q3 was $32.2M vs $40.2M in Q3 2025, down 19.9% due to higher capex and working capital
- Transition services agreement with Select Medical expires in November 2026, introducing potential operational complexity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002014596-26-000070 |
| Document: cghp-20261104.htm | 0002014596-26-000070 |
| Document: concentrainvestorpresent.htm | 0002014596-26-000070 |
| Document: 0002014596-26-000070-index-headers.html | 0002014596-26-000070 |
| Document: 0002014596-26-000070-index.html | 0002014596-26-000070 |
| Document: 0002014596-26-000070.txt | 0002014596-26-000070 |
| 8-K Data (Synthetic) | 0002014596-26-000070 |
Track record
13 reports on CON
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +8.49% at T+1 after the Nov 3, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 20261d ago SC 13D/A Neutral 4/10 Entry $42.40 Now $43.45 +2.48% settles Nov 12
- Nov 10, 20261d ago 8-K Neutral 3/10 Entry $42.40 Now $43.45 +2.48% settles Nov 12
- Nov 9, 20262d ago 8-K Neutral 2/10 Entry $42.67 to $43.45 Now $43.45 +1.83% ▲ +1.83% +0.51% vs SPY
- Nov 5, 20266d ago 3 Neutral 2/10 Entry $42.22 to $42.40 Now $43.45 +2.91% ▲ +0.43% −1.94% vs SPY
- Nov 5, 20266d ago 8-K Bullish 6/10 Viewing Entry $42.22 to $42.40 Now $43.45 +2.91% ▲ +0.43% −1.94% vs SPY
- Nov 3, 20268d ago Institutional Cluster Bullish 4/10 Entry $40.15 to $43.56 Now $43.45 +8.22% ▲ +8.49% +6.84% vs SPY
- Jun 30, 202619w ago 144 Neutral 2/10 Entry $30.77 to $31.91 Now $43.45 +41.21% ▲ +3.70% +3.84% vs SPY
- Jun 29, 202619w ago 144 Neutral 2/10 Entry $29.75 to $30.77 Now $43.45 +46.05% ▲ +3.43% +3.56% vs SPY
- Jun 26, 202619w ago 144 Neutral 3/10 Entry $29.77 to $29.75 Now $43.45 +45.95% ▼ −0.07% −0.85% vs SPY
- Jun 1, 202623w ago 144 Bearish 5/10 Entry $25.09 to $24.75 Now $43.45 −73.18% ▲ +1.36% +0.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers